Evidence map›Paper›PMID 36714226›Full record

ArticleCurrent urology2022

Association between ABO blood group and unfavorable prostate cancer features after radical prostatectomy: Retrospective study of 1149 patients.

Antonio Benito Porcaro, Nelia Amigoni, Riccardo Rizzetto, Filippo Migliorini, Alessandro Tafuri, Pierluigi Piccoli, Leone Tiso, Mario De Michele, Alberto Bianchi, Sebastian Gallina and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Antonio Benito PorcaroDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Nelia AmigoniDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Riccardo RizzettoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Filippo MiglioriniDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Alessandro TafuriDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Pierluigi PiccoliDepartment of Transfusion Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Leone TisoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Mario De MicheleDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Alberto BianchiDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Sebastian GallinaDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Paola Irene OrnaghiDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Rossella OrlandoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Francesco CianfloneDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Alessandra GozzoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Stefano Zecchini AntoniolliDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Vincenzo LacolaDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Matteo BrunelliDepartment of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Maria Angela CerrutoDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Walter ArtibaniDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Alessandro AntonelliDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To test hypothesized associations between the ABO blood group (ABO-bg) system and the pathological features of prostate cancer (PCa). Material and methods: Between January 2013 and September 2019, 1173 patients underwent radical prostatectomy. Associations between ABO-bg levels and pathological features were evaluated using statistical methods. Results: Overall, 1149 consecutive patients were evaluated using the ABO-bg system, which was represented by O-bg (42.8%) and A-bg (41.3%), followed by B-bg (11.1%) and AB-bg (4.8%). Only positive surgical margins (PSMs) was correlated with ABO-bg (Pearson correlation coefficient, Conclusions: In clinical PCa, the risk of PSM was higher in O-bg versus non-O-bg patients after the adjustment for standard predictors. Confirmatory studies are needed to confirm the association between ABO-bg and unfavorable PCa features.

Indexed as

ABO blood systemProstate cancerRadical prostatectomyTumor loadTumor stage

Identifiers

PMID36714226
PMCPMC9875211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.